The Effect of Antifibrotics on the Progression of Pulmonary Hypertension in Patients with Interstitial Lung Disease Listed for Lung Transplantation

Purpose: The antifibrotics (AF) nintedanib and pirfenidone are known to attenuate the progression of fibrotic interstitial lung disease (ILD). It is unknown if these drugs affect the development of pulmonary hypertension (PH) in patients with ILD. We characterized the change in mean pulmonary arterial pressure (mPAP) in patients with ILD who were listed for lung transplantation (LTx) and explored if pre-operative AF therapy was associated with the rate of change of mPAP.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Source Type: research